IsomAb

IsomAb is a private, preclinical-stage biotech focused on a first-in-class antibody therapy for coronary artery disease, specifically chronic stable angina. The company's scientific foundation, supported by prestigious UK research grants, targets VEGF-A165b to unlock therapeutic angiogenesis and address an unmet need in a large patient population. Led by an experienced management team with strong cardiovascular and biotech venture backgrounds, IsomAb is positioned to advance its lead candidate toward clinical development in a high-value market with limited competition in disease-modifying approaches.

Platform for developing isoform-specific antibodies, initially targeting the anti-angiogenic VEGF-A165b isoform to promote therapeutic blood vessel growth (arteriogenesis).

Direct competition is limited, as no approved therapies specifically promote therapeutic arteriogenesis. IsomAb competes with generic symptom-relief drugs and invasive procedures (stents, bypass). Other angiogenesis-focused approaches (e.g., gene therapy with FGF) have historically struggled, leaving the field open for a novel, targeted biologic like ISM-001.